Investment Thesis
Beyond Air is a pre-commercial medical device company with only $5.8M in revenue but $23M in annual losses and $13.7M free cash burn, leaving approximately 6 months of runway with $6.6M in cash. A 2.7% gross margin and -379% operating margin indicate fundamental business model failures at current scale, while $22M in long-term debt cannot be serviced from deeply negative cash flows.
Strengths
- Medical device sector offers high-growth potential if product achieves regulatory approval and market adoption
- Strong current ratio (5.12x) and quick ratio (4.77x) provide adequate short-term liquidity coverage
- Net loss and diluted EPS improved year-over-year, indicating some operational trending positive from prior period
Risks
- Critical liquidity crisis: 6-month cash runway at current $13.7M annual free cash burn rate without capital raise or revenue acceleration
- Catastrophically low gross margin (2.7%) and operating margin (-379%) indicate fundamental business model dysfunction or severe pricing/cost structure problems
- Unsustainable debt burden: $22M long-term debt with negative interest coverage (-7.5x) cannot be serviced from negative operating cash flows, requiring immediate refinancing or capital injection
Key Metrics to Watch
- Monthly cash burn rate and cash balance trajectory - critical for survival timeline and capital raise necessity
- Revenue growth and gross margin expansion - required to achieve path toward operating profitability
- Debt refinancing activities and equity capital raises - essential indicators of whether the company can extend its runway
Financial Metrics
Revenue
5.8M
Net Income
-23.0M
EPS (Diluted)
$-3.44
Free Cash Flow
-13.7M
Total Assets
36.8M
Cash
6.6M
Profitability Ratios
Gross Margin
2.7%
Operating Margin
-379.0%
Net Margin
-397.9%
ROE
-283.2%
ROA
-62.5%
FCF Margin
-236.9%
Balance Sheet & Liquidity
Current Ratio
5.12x
Quick Ratio
4.77x
Debt/Equity
2.71x
Debt/Assets
77.5%
Interest Coverage
-7.51x
Long-term Debt
22.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-19T12:30:22.295208 |
Data as of: 2025-12-31 |
Powered by Claude AI